ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO ® (lanadelumab) for subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback